TY - JOUR
T1 - Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence
AU - Krabbe, Laura Maria
AU - Woldu, Solomon L.
AU - Shariat, Shahrokh F.
AU - Lotan, Yair
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.
AB - Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.
KW - Bladder cancer
KW - follow-up
KW - molecular biomarker
KW - non-muscle invasive
KW - surveillance
KW - transitional cell carcinoma
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84992730290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992730290&partnerID=8YFLogxK
U2 - 10.1080/14737159.2016.1244006
DO - 10.1080/14737159.2016.1244006
M3 - Review article
C2 - 27696932
AN - SCOPUS:84992730290
SN - 1473-7159
VL - 16
SP - 1189
EP - 1199
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 11
ER -